Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder
Kiluk BD, Yip SW, DeVito EE, Carroll KM, Sofuoglu M. Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder. Clinical Psychological Science 2019, 7: 1190-1206. PMID: 32042509, PMCID: PMC7009780, DOI: 10.1177/2167702619855659.Peer-Reviewed Original ResearchOpioid use disorderClinical featuresUse disordersHigher anhedonia scoresKey clinical featuresRate of participantsAnhedonia scoresOpioid-dependent sampleOpioid cravingOpioid useTreatment adherenceHealthy controlsSignificant anhedoniaPharmacological interventionsAssessment of anhedoniaMajority of studiesPotential targetAnhedoniaTreatmentTime courseDisordersSignificant knowledge gapsScoresPotential implicationsCritical needDouble‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use
Carroll KM, DeVito EE, Yip SW, Nich C, Sofuoglu M. Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. American Journal On Addictions 2019, 28: 238-245. PMID: 31165574, PMCID: PMC9078084, DOI: 10.1111/ajad.12904.Peer-Reviewed Original ResearchConceptsMethadone-maintained individualsOpioid useSecondary analysisMultiple drugsConcurrent cocaine dependenceTrial of galantaminePlacebo-controlled trialDouble-blind placeboIllicit opioid useRandomized clinical trialsCocaine use disorderGalantamine's effectFuture trialsClinical trialsUrine specimenUrine specimensUse disordersOpioidsCholinesterase inhibitorsMaintenance settingCocaine useCocaine dependencePlaceboConcurrent useGalantamine